at ASCO meeting, poster presenter on measuring tumor markers in the CSF

[Lani]

(cerebral spinal fluid) in those with leptomeningeal metastasis

She had not looked at it in her2+ patients-- I suggested since there are now more patients receiving intrathecal herceptin, perhaps they should look at that as one way to monitor if it is working and see if efficacy and CSF biomarker are correlated.

Courtney--are they taking CSF samples and testing it for tumor cells or tumor markers to see how they are changing?

You are a pioneer and let's hope others can benefit from your experience